Trident Texofab Intrinsic Value
Trident Texofab (TTFL) median intrinsic value is ₹33.57 from 9 valuation models (range ₹20–₹71), vs current price ₹43.21 — -22.3% downside (Trading Above Calculated Value), margin of safety -28.7%. Also explore TTFL price movement history to track price trends across different timeframes.
TTFL Valuation Methods Summary — DCF, Graham Number & P/E
Trident Texofab intrinsic value across 9 models vs current price ₹43.21 — upside/downside and value range per method. For current market price and key ratios, visit TTFL share price.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹28.80 | ₹23.04 - ₹34.56 | -33.3% | EPS: ₹2.40, Sector P/E: 12x |
| Book Value Method | asset | ₹33.57 | ₹30.21 - ₹36.93 | -22.3% | Book Value/Share: ₹33.57, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹70.86 | ₹63.77 - ₹77.95 | +64.0% | Revenue/Share: ₹88.57, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹38.57 | ₹34.71 - ₹42.43 | -10.7% | EBITDA: ₹9.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹28.54 | ₹22.83 - ₹34.25 | -34.0% | CF Growth: 14.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹38.40 | ₹34.56 - ₹42.24 | -11.1% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹20.15 | ₹18.13 - ₹22.16 | -53.4% | Revenue Growth: 9.9%, Adj P/E: 8.4x |
| ROE Based Valuation | profitability | ₹21.61 | ₹19.45 - ₹23.77 | -50.0% | ROE: 6.4%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹42.58 | ₹38.32 - ₹46.84 | -1.5% | EPS: ₹2.40, BVPS: ₹33.57 |
TTFL Intrinsic Value vs Market Price — All Valuation Models
Trident Texofab fair value range ₹20–₹71 vs current market price ₹43.21 across 9 valuation models. Browse TTFL annual financials for revenue, profit, balance sheet and cash flow data.
TTFL Intrinsic Value Analysis — Undervalued or Overvalued?
Trident Texofab median intrinsic value ₹33.57, current price ₹43.21 — Trading Above Calculated Value by 22.3%, margin of safety -28.7%.
What is the intrinsic value of TTFL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Trident Texofab (TTFL) is ₹33.57 (median value). With the current market price of ₹43.21, this represents a -22.3% variance from our estimated fair value.
The valuation range spans from ₹20.15 to ₹70.86, indicating ₹20.15 - ₹70.86.
Is TTFL undervalued or overvalued?
Based on our multi-method analysis, Trident Texofab (TTFL) appears to be trading above calculated value by approximately 22.3%.
TTFL Financial Health — Key Ratios vs Industry Benchmarks
Trident Texofab financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.69 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.4% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.23x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
TTFL Cash Flow Quality — Operating & Free Cash Flow
Trident Texofab operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-14 Cr | ₹-24 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹6 Cr | ₹6 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹2 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |